絞り込み

16636

広告

Disease Modification in Alzheimer's Disease: Current Thinking.

著者 Liu-Seifert H , Schumi J , Miao X , Tian Y , Rabbia M , Andersen SW , Wilson S , Li W , Entsuah R
Ther Innov Regul Sci.2019 Apr 14 ; ():2168479019841894.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (28view , 0users)

Full Text Sources

Alzheimer's disease (AD) has increasingly been recognized as a huge unmet medical need. Currently, there is no approved drug to cure, prevent, or even slow down the disease. It is imperative to develop disease-modifying treatments for AD to alter the underlying disease progression. This paper reviews the most up-to-date regulatory guidance on how to demonstrate disease modification and provides an overview of available methodologies and applications to clinical trials. The intent is to assist the field with future clinical trials designed to demonstrate disease-modifying effect in AD. The methodologies may be generalizable to broader neurodegenerative diseases.
PMID: 30983382 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード